Previous 10 | Next 10 |
Kymera Therapeutics (KYMR) announces positive interim results from the Single Ascending Dose ((SAD)) portion of the Phase 1 trial of KT-474, demonstrating the first degrader proof-of-mechanism in targeted protein degradation in a healthy volunteer study.Following a single 300 mg dose of KT-47...
KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose After single dose administration, degradation was maintained for at least six days at all dose levels...
Kymera Therapeutics (KYMR) announces the appointment of Elaine Caughey as the company's chief business officer.Caughey joins Kymera with over 20 years of experience in the biotechnology industry, including leadership roles in corporate development, business and commercial opera...
WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elaine Caughey, MBA,...
Kymera Therapeutics ([[KYMR]] -0.8%) posts new preclinical data on its IRAKIMiD degrader KT-413’s potential as both a monotherapy and in combination with other anticancer agents.KT-413 showed synergistic activity in driving deep tumor regressions in combination with other therapies in ...
Data presented at the 16th ICML Meeting demonstrate KT-413’s potent antitumor activity as a monotherapy compared to a clinically active IRAK4 kinase inhibitor or a latest generation IMiD in MYD88-mutant mouse xenograft model KT-413 shows synergistic activity in driving de...
Data demonstrate KT-413’s potential as a monotherapy and in combination with rituximab or BTK inhibitors, with potent antitumor activity in multiple xenograft models of MYD88 MT DLBCL WATERTOWN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. ...
WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a ...
The following slide deck was published by Kymera Therapeutics, Inc. in conjunction with this event. For further details see: Kymera Therapeutics (KYMR) Presents At Ligase Targeting Drug Development Summit - Slideshow
The following slide deck was published by Kymera Therapeutics, Inc. in conjunction with this event. For further details see: Kymera Therapeutics (KYMR) Presents At UBS Global Healthcare Virtual Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...